Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating ...

Marstacimab (PF-06741086) 是一种抗组织因子通路抑制剂 (TFPI) 单克隆抗体。Marstacimab 可用于血友病的研究。 Marstacimab (20，50 和 100 nmol/L) 降低血友病患者的全血样本中的玉米胰蛋白酶 (CT)[1]。 Marstacimab (16 μg/mL) 可缩短体外培养的人非 ...

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia. The recommendation by the EMA's ...

Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year. Marstacimab will be ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% compared to on-demand treatment with bypassing agents in patients with ...

▎药明康德出血率降低93%！辉瑞血友病疗法达3期主要与次要终点辉瑞（Pfizer）今日宣布其评估TFPI靶向抗体Hympavzi（marstacimab）用于体内存有抑制物的血友病A或血友病B成人和青少年患者的3期BASIS研究获得积极顶线结果。该研究达到了主要终点和关键的次要出血终点，结果显示每周一次皮下注射Hympavzi在改善关键出血结局方 ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and showing good tolerability.

Pfizer announces positive results from phase 3 BASIS study of Hympavzi in haemophilia A or B with inhibitors: New York Friday, June 27, 2025, 10:00 Hrs [IST] Pfizer Inc. announced ...

Pfizer’s Hympavzi, given as a once-weekly subcutaneous injection using a pre-filled pen, works by reducing the amount of TFPI ...